Interleukin 4

News and Video Search Results

News coverage

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

PR Newswire Asia 03 Jun 2024

CHENGDU, China, June 3, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and..

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
GlobeNewswire 31 May 2024
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Accesswire 31 May 2024
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31 May 2024
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 31 May 2024

0 shares 1 views

You might like

Interleukin 4 media coverage

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

GlobeNewswire 31 May 2024

Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2..

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
GlobeNewswire 31 May 2024
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
PR Newswire Asia 28 May 2024